Aqua(2,2'-bi-1H-imidazole)chlorocopper(II) chloro(iminodiacetato)copper(II) monohydrate.

In the title compound, [CuCl(C6H6)N4)(H2O)][Cu(C4H5NO4)Cl].H2O, the Cu(II) atom in the cation is coordinated by one Cl- ion, two N atoms of the 2,2'-biimidazole ligand and one aqua ligand. Within the anion, the Cu(II) atom is bonded to one Cl- ion, and one N and two O atoms of the iminodiacetate ligand.

Hemi[hexaaquamagnesium(II)] (mu-2,6-bis[[bis(carboxylatomethyl)amino]methyl]-4-chlorophenolato)bis[diaquamagnesium(II)] decahydrate.

The crystal structure of the title compound, [Mg(H2O)6]0.5[Mg2(C16H14ClN2O9)(H2O)4].10H2O, shows that this binuclear complex consists of two Mg centres in distorted octahedral geometry, joined by an oxo bridge which is a derivative of the deprotoned hydroxy group of the phenolate in the ligand molecule.

Study on the amount of binding of anti-tumor metal complexes to different target sites of dGMP using trans-[en(2)Os(eta2-H(2))(CF(3)SO(3))](CF(3)SO(3)) in a competitive mode.

In order to investigate the binding sites and the amount of binding of a number of anti-tumor metal complexes (cisplatin, Cp(2)TiCl(2) and (CH(3))(2)SnCl(2)) to target molecule DNA mononucleotides in aqueous solution, a 1H NMR recognition probe, trans-[en(2)Os(eta2-H(2))(CF(3)SO(3))](CF(3)SO(3)), was used in a competitive mode. The minimum percentages of binding of anti-tumor metal complexes to different sites of dGMP were also determined.